Jump to ContentJump to Main Navigation

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

4 Issues per year


IMPACT FACTOR 2014: 0.912
5-year IMPACT FACTOR: 1.485

SCImago Journal Rank (SJR): 0.478
Source Normalized Impact per Paper (SNIP): 1.096

Open Access
VolumeIssuePage

Issues

Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections

Farhan Ahmad1 / Mohd Alam1 / Zeenat Khan1 / Roop Khar1 / Mushir Ali1

Department of Pharmaceutics, Hamdard University, New Delhi-110062, India1

This content is open access.

Citation Information: Acta Pharmaceutica. Volume 58, Issue 4, Pages 407–419, ISSN (Online) 1846-9558, ISSN (Print) 1330-0075, DOI: 10.2478/v10007-008-0023-2, December 2008

Publication History

Published Online:
2008-12-22

Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections

An acid buffering bioadhesive vaginal (ABBV) gel was developed for the treatment of mixed vaginal infections. Different bioadhesive polymers were evaluated on the basis of their bioadhesive strength, stability and drug release properties. Bioadhesion and release studies showed that guar gum, xanthan gum and hydroxypropyl methylcelullose K4M formed a good combination of bioadhesive polymers to develop the ABBV gel. Monosodium citrate was used as an acid buffering agent to provide acidic pH (4.4). The drugs clotrimazole (antifungal) and metronidazole (antiprotozoal as well as antibacterial) were used in the formulation along with Lactobacillus spores to treat mixed vaginal infections. The ex vivo retention study showed that the bioadhesive polymers hold the gel for 12-13 hours inside the vaginal tube. Results of the in vitro antimicrobial study indicated that the ABBV gel had better antimicrobial action than the commercial intravaginal drug delivery systems and retention was prolonged in an ex vivo retention experiment.

Razvoj i in vitro vrednovanje puferiranog bioadhezivnog vaginalnog gela za miješane vaginalne infekcije

U radu je opisan razvoj puferiranog biodhezivnog vaginalnog (acid buffering bioadhesive vaginal, ABBV) gela za terapiju miješanih vaginalnih infekcija. Ispitani su različiti bioadhezivni polimeri - procijenjena su njihova bioadhezivna svojstva, stabilnost i sposobnost oslobađanja ljekovite tvari. Guar guma, ksantan guma i hidroksipropilmetilceluloza K4M tvore dobru kombinaciju za ABBV gel. Mononatrijev citrat upotrebljen je kao puferirajuća tvar koja omogućava blago kiseli pH (4,4), a kao ljekovite tvari upotrebljeni su klotrimazol (antimikotik) i metronidazol (antiprotozoik i antibakterijsko sredstvo), zajedno sa sporama Lactobacillus. Pripravci su upotrebljeni u terapiji miješanih vaginalnih infekcija. Pokusi ex vivo pokazali su da se bioadhezivni gel zadržava u vagini 12-13 sati. Rezultati in vitro ispitivanja ukazuju na to da ABBV gel ima bolje antibakterijsko djelovanje i dulje zadržavanje od intravaginalnog sustava koji je dostupan na tržištu.

Keywords: acid buffering gel; vaginal bioadhesion; bioadhesive polymers; mixed vaginal infections

Keywords: puferirani gel; vaginalna bioadhezija; bioadhezivni polimeri; miješane vaginalne infekcije

  • J. Sherrard, European guidelines for the management of vaginal discharge, Int. J. STD AIDS 12 (2001) 73-77. [PubMed]

  • S. Kukner, T. Ergin, N. Cicek, M. Ugur, H. Yesilyurt and O. Gokmen, Treatment of vaginitis, Int. J. Gynecol. Obstet. 52 (1996) 43-47; DOI: 10.1016/0020-7292(95)02531-6. [CrossRef]

  • Vaginitis ACOG Technical Bulletin, Int. J. Gynecol. Obstet. 53 (1996) 271-280; DOI: 10.1016/S0020-7292(96)90014-4. [CrossRef]

  • P. A. Mardh, K. Tchoudomirova, S. Elshibly and D. Hellberg, Symptoms and signs in single and mixed genital infections, Int. J. Gynecol. Obstet. 63 (1998) 145-152; DOI: 10.1016/S0020-7292(98)00140-4. [CrossRef]

  • E. Ozyurt, M. B. Toykuliyeva, I. L. Danilyans, O. Morton and G. Baktir, Efficacy of 7-day treatment with metronidazole + miconazole (Neo-Penotran®) - a triple-active pessary for the treatment of single and mixed vaginal infections, Int. J. Gynecol. Obstet. 74 (2001) 35-43; DOI: 10.1016/S0020-7292(01)00388-5. [CrossRef]

  • J. Thinkhamrop, P. Lumbiganon, P. Thongkrajai and C. Chongsomchai, Vaginal pH as a screening test for vaginitis, Int. J. Gynecol. Obstet. 66 (1999) 143-148; DOI: 10.1016/S0020-7292(99) 00057-0. [CrossRef]

  • G. C. Ceschel, P. Maffei, S. L. Borgia, C. Ronchi and S. Rossi, Development of a mucoadhesive dosage form for vaginal administration, Drug Dev. Ind. Pharm. 27 (2001) 541-547; DOI: 10.1081/DDC-100105179. [PubMed] [Web of Science] [CrossRef]

  • K. Vermani and S. Garg, The scope and potential of vaginal drug delivery, Pharm. Sci. Technol. Today 3 (2000) 359-364; DOI: 10.1016/S1461-5347(00)00296-0. [CrossRef] [PubMed]

  • R. S. Levinson and D. J. Thompson, VagiSite bioadhesive technology, Drugs Pharm. Sci. 126 (2003) 801-806.

  • C. D. Freeman, N. E. Klutman and K. C. Lamp, Metronidazole, a therapeutic review and update, Drugs 54 (1997) 679-708. [PubMed]

  • P. H. Spiekermann and M. D. Young, Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent, Arch. Dermatol. 112 (1976) 350-352. [PubMed]

  • L. Maggi, P. Mastromarino, S. Macchia, P. Brigidi, F. Pirovano, D. Matteuzzi and U. Conte, Technological and biological evaluation of tablets containing different strains of Lactobacilli for vaginal administration, Eur. J. Pharm. Biopharm. 50 (2000) 389-395; DOI: 10.1016/S0939-6411(00)00121-1. [CrossRef]

  • D. H. Owen and D. F. Katz, A vaginal fluid stimulant, Contraception 59 (1999) 91-95; DOI: 10.1016/S0010-7824(99)00010-4. [CrossRef]

  • United States Pharmacopoeia 26 - National Formulary 21, Asian Edition, USP Convention, Rockville (MD) 2003, pp. 2155-2156.

  • H-L. Weng and E. L. Parrott, Dissolution apparatus for gels, J. Pharm. Sci. 72 (1983) 186-188; DOI: 10.1002/jps.2600720223. [CrossRef]

  • M. A. Alam, F. J. Ahmad, Z. I. Iqubal, R. K. Khar and M. Ali, Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections, AAPS PharmSciTech. 8 (2007) 229-236.

  • I. C. De Paula, G. G. Ortega, V. L. Bassani and P. R. Petrovick, Development of ointment formulations prepared with Achyrocline satureioides spray dried extracts, Drug Dev. Ind. Pharm. 24 (1998) 235-241.

  • L. Kaus, Buffers and Buffering Agents, in Encyclopedia of Pharmaceutical Technology (Eds. J. Swarbrick and J. C. Boylan), Vol. 2, Marcel Dekker, New York 1990, pp. 213-231.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jyoti Gupta, Jason Qihai Tao, Sanjay Garg, and Raida Al-Kassas
Pharmacology & Pharmacy, 2011, Volume 02, Number 04, Page 289
[2]
Carla M. Caramella, Silvia Rossi, Franca Ferrari, Maria Cristina Bonferoni, and Giuseppina Sandri
Advanced Drug Delivery Reviews, 2015
[4]
Himmat Singh Johal, Tarun Garg, Goutam Rath, and Amit Kumar Goyal
Drug Delivery, 2014, Page 1
[5]
Prithviraj Chakraborty, Surajit Dey, Versha Parcha, Shiv Sankar Bhattacharya, and Amitava Ghosh
BioMed Research International, 2013, Volume 2013, Page 1
[6]
Prithviraj Chakraborty, Versha Parcha, Debarupa D. Chakraborty, Indranil Chanda, and Amitava Ghosh
Journal of Pharmaceutical Investigation, 2013, Volume 43, Number 2, Page 133
[7]
A. Palmeira- de-Oliveira, R. Palmeira- de-Oliveira, C. Gaspar, L. Salgueiro, C. Cavaleiro, J. Martinez- de-Oliveira, J.A. Queiroz, and A.G. Rodrigues
Flavour and Fragrance Journal, 2013, Volume 28, Number 6, Page 354
[8]
Sara S. Santos, Alessandra Lorenzoni, Luana M. Ferreira, Juliane Mattiazzi, Andréa I.H. Adams, Laura B. Denardi, Sydney H. Alves, Scheila R. Schaffazick, and Letícia Cruz
Materials Science and Engineering: C, 2013, Volume 33, Number 3, Page 1389
[9]
Raphaela Regina de Araújo Pereira and Marcos Luciano Bruschi
Drug Development and Industrial Pharmacy, 2012, Volume 38, Number 6, Page 643

Comments (0)

Please log in or register to comment.